Orexo AB has announced that its partner, UK-based international specialty pharmaceutical company ProStrakan Group plc, has submitted the New Drug Application (NDA) for Abstral™ (for the treatment of breakthrough cancer pain in opioid-tolerant patients) to the US Food and Drug Administration (FDA).
The filing of AbstralTM will generate a milestone payment to Orexo as part of the agreement with ProStrakan for North America that in total can give USD 27 million in certain regulatory and sales milestone payments. In addition, Orexo will receive royalties on product sales.
Commenting on the filing, Torbjörn Bjerke, Orexo’s President and CEO, said: “This submission is the first stage of bringing Abstral™ to the thousands of patients in the USA we believe will benefit from this novel, convenient and effective treatment. The US market is the world’s largest market for breakthrough cancer pain with the number of breakthrough cancer pain attacks amounting to approximately 376 million per year(1). We are excited about the prospect of a US launch of Abstral™ by ProStrakan, Orexo’s partner for AbstralTM in both North America and Europe.”
The filing of Abstral™ has yet to be validated by the FDA before being accepted for review, and therefore no PDUFA date has yet been assigned.
1) Source: Datamonitor 2006, Pipeline Insight: Breakthrough Pain
Abstral is a fast-dissolving tablet for sub-lingual administration of fentanyl, intended for the management of breakthrough cancer pain in patients who are already receiving opioid analgesics. It is based on Orexo’s unique and patented sublingual tablet technology in which a rapidly dissolving tablet is placed under the tongue and the active substance is absorbed by the mucous membrane. Currently AbstralTM is sold in Sweden, UK, Germany and France. The product is also being prepared for registration in Japan.
License agreements for AbstralTM have been signed with ProStrakan for Europe and North America and with Kyowa Hakko Kirin for Japan. Distribution agreements regarding AbstralTM for Russia and the CIS, Bulgaria and Rumania have been signed with Gedeon Richter. A distribution agreement has been signed with Hospira for the Southeast Asian market. For the Chinese market, Orexo has signed a distribution agreement with NovaMed, and for the Israeli market Orexo has signed a distribution agreement with Neopharm.
AI models redefine TIL scoring in breast cancer but face challenges in real-world validation